A study of nearly 200 breast cancer patients has identified a previously overlooked feature of the immune system that appears to shape how the disease progresses: the microscopic scaffolding inside lymph nodes that channels fluid and immune cells through the tissue.
Researchers from King’s College London and University College London examined over 300 axillary lymph nodes — the nodes under the arm that are often the first place breast cancer spreads to — from 179 patients, alongside 23 tumor-free nodes from people with benign conditions. Their focus was a network of stromal cells called fibroblastic reticular cells (FRCs), which form a fine collagen mesh that guides the flow of lymph fluid and helps immune cells find and respond to threats, including cancer cells.
A network that changes shape with disease
Using a specialized antibody marker and an automated image-analysis pipeline originally built to study other tissue matrices, the team mapped how this reticular network’s architecture — its density, branching pattern, and fiber alignment — differed between healthy nodes, nodes free of cancer in patients with breast cancer, and nodes invaded by tumor.
The differences were substantial. Reactive, cancer-free nodes clustered separately from cancer patients’ nodes in the analysis, even when those patient nodes had no detectable tumor cells — suggesting that breast cancer somehow reshapes the network in lymph nodes it hasn’t yet reached. In patients with triple-negative breast cancer, an aggressive subtype, cancer-free nodes showed a denser, more tightly branched network than nodes from patients with HER2-positive disease, independent of any treatment received.
When density helps and when it hurts
The relationship between this network density and patient survival turned out to depend heavily on context. Among triple-negative breast cancer patients who had no residual disease in their nodes after chemotherapy, a denser network was linked to better overall survival. Chemotherapy itself appeared to push nodes toward this denser architecture, and that shift correlated with improved outcomes in that specific patient group.
But the opposite held true elsewhere. In patients whose cancer had already spread to one to three lymph nodes, a denser network in the still-cancer-free nodes nearby was associated with significantly worse survival, regardless of treatment history. And within nodes actually invaded by tumor, once network distortion crossed a certain threshold — measured by a metric called lacunarity, which captures how much open space exists in the mesh — survival dropped significantly. Conversely, when the remaining fibers in a tumor deposit were more aligned rather than scattered, patients tended to fare better.
What chemotherapy leaves behind
The study also examined what happens to lymph node tissue after chemotherapy successfully destroys a tumor. In areas where treatment had eliminated cancer, the delicate reticular mesh was often replaced by dense, mature scar-like collagen, with very few of the original stromal cells remaining and few immune cells present. The researchers suggest this fibrotic remodeling could have consequences for how well the node continues to support immune surveillance after treatment.
Why it matters
The findings, published as a preprint and not yet peer-reviewed, offer a potential new lens for understanding why some lymph nodes still manage to mount an effective anti-tumor response while others fail — a question that currently has no reliable biomarker. The research team believes this network architecture could eventually help refine decisions about how much lymph node tissue needs to be surgically removed, a balance surgeons already weigh carefully given the risk of lymphedema, or arm swelling, from more extensive node removal.
The authors caution that their patient cohort, while substantial, was drawn from a single hospital, and that reversibility of these tissue changes over time remains unclear. They say they now plan to use a real-time fluid-perfusion model of human lymph nodes to test directly how altered network architecture affects fluid flow and immune function — work aimed at turning this structural observation into a usable clinical tool.
